Trial Profile

An Observational Cohort Study of the Use of Avatrombopag in Patients With Thrombocytopenia Associated With Chronic Liver Disease Undergoing a Procedure

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avatrombopag (Primary)
Indications Thrombocytopenia
Focus Therapeutic Use
Sponsors Dova Pharmaceuticals

Most Recent Events

26 Jun 2021 Results assessing the effectiveness safety and treatment patterns of the thrombopoietin receptor agonist avatrombopag (AVA) in patients with thrombocytopenia associated with CLD presented at The International Liver Congress 2021
06 Mar 2019 Status changed from recruiting to discontinued.
22 Jun 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com